Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:TLSI

TriSalus Life Sciences Q3 2026 Earnings Date & Estimates

TriSalus Life Sciences logo
$3.63 -0.27 (-6.92%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$3.66 +0.02 (+0.69%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TriSalus Life Sciences is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from TriSalus Life Sciences in Q3 2026

TriSalus Life Sciences is expected to post earnings of -$0.14 per share on revenue of $14.02 million. In the same quarter a year earlier TriSalus Life Sciences reported -$0.96 per share on revenue of $11.57 million. TriSalus Life Sciences last reported on August 6, 2026, posting -$0.16 per share and missing the -$0.1550 consensus estimate. TriSalus Life Sciences has beaten the consensus EPS estimate in 1 of its last 6 quarters.

Consensus Estimates

Consensus EPS
-$0.14
Expected Revenue
$14.02 million
Prior-Year EPS
-$0.96
Prior-Year Revenue
$11.57 million
Expected Revenue Growth
+21.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.16 (Missed by -$0.0050)
Last Quarter Revenue
$11.41 million
EPS Beat Rate
1 of last 6 quarters

Prepare for the Q3 2026 Call

TriSalus Life Sciences Q3 2026 Earnings FAQ

TriSalus Life Sciences (NASDAQ:TLSI) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

TriSalus Life Sciences' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect TriSalus Life Sciences to post earnings of -$0.14 per share for Q3 2026.

The consensus revenue estimate for TriSalus Life Sciences is $14.02 million for Q3 2026.

TriSalus Life Sciences Earnings Headlines

H.C. Wainwright Keeps Their Buy Rating on TriSalus Life Sciences (TLSI)
October 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLSI/pressreleases/4925316/hc-wainwright-keeps-their-buy-rating-on-trisalus-life-sciences-tlsi/
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH), TriSalus Life Sciences (TLSI) and Immuneering (IMRX)
September 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLSI/pressreleases/4749955/analysts-offer-insights-on-healthcare-companies-faeth-therapeutics-fth-trisalus-life-sciences-tlsi-and-immuneering-imrx/
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
 |  Stansberry Research (Ad)
Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (TLSI) and Eli Lilly & Co (LLY)
September 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLSI/pressreleases/4779116/analysts-conflicted-on-these-healthcare-names-trisalus-life-sciences-tlsi-and-eli-lilly-co-lly/
TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance
September 24, 2026  |  marketscreener.comM
Update: TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/trisalus-life-sciences-shares-rise-182155883.html
See More TriSalus Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TriSalus Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TriSalus Life Sciences and other key companies, straight to your email.

About TriSalus Life Sciences

TriSalus Life Sciences (NASDAQ:TLSI) is an oncology-focused life sciences company developing medical technologies and therapies for patients with difficult-to-treat liver and pancreatic tumors. The company’s approach is designed to address the unique biological and physical barriers that can limit the delivery of cancer treatments to solid tumors.

TriSalus’ principal technology is its Pressure-Enabled Drug Delivery (PEDD) platform, which is intended to improve the distribution of therapeutic agents within tumors through regional infusion. The company’s TriNav Infusion System is used to support targeted delivery procedures, including treatments involving the liver and pancreas. TriSalus also develops investigational immuno-oncology therapies intended for use with its delivery platform and other cancer treatments.

The company’s clinical and commercial activities focus primarily on oncology applications in the United States, particularly hepatocellular carcinoma, intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. TriSalus has expanded its capabilities through the development and acquisition of drug-delivery and immunotherapy technologies. The company is led by Chief Executive Officer Steve Damon.

View TriSalus Life Sciences Profile
Earnings Tools